BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 05, 2008
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 1Q08 EPS est 1Q08 EPS actual Outcome Growth from 1Q07 5/2 cls Wk chg % chg Mcap chg 5/2 Mcap
Cephalon (NASDAQ:CEPH) $0.96 $1.02 Beat by $0.06 -18% $60.58 -$1.42 -2% -$96.1 $4,099.1
Cephalon reported 1Q08 revenues of $443.2M, up from $437M in the prior year's quarter. SG&A expenses rose 30% to $199M, due in part to costs associated with the launches of Treanda bendamustine to treat chronic lymphocytic leukemia (CLL) and Amrix, an extended-release formulation of cyclobenzaprine for muscle spasms associated with musculoskeletal conditions....

Read the full 745 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >